All the news Showing 10 of 53 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial Liz Highleyman / 06 November 2013 A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response (SVR12) in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course ... Two new hepatitis C drugs recommended for US approval Keith Alcorn / 02 November 2013 Two new direct acting antiviral agents for the treatment of hepatitis C have been unanimously recommended for approval by expert advisory panels in the United States. Full marketing approval from the US ... Faldaprevir demonstrates good early response in genotype 1 HIV/HCV co-infection Liz Highleyman / 22 October 2013 The HCV protease inhibitor faldaprevir added to pegylated interferon and ribavirin increased the likelihood that HIV/HCV co-infected people would achieve a sustained virological response at four weeks after completing treatment, according to a ... Physicians are Foregoing Treatment of Their HCV Patients Until New Agents Become Available BioTrends / 06 August 2013 Interferon-free simeprevir + sofosbuvir suppresses hepatitis C with or without ribavirin Liz Highleyman / 17 June 2013 An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment sustained response for most prior null responders with genotype 1 hepatitis C in ... Boceprevir benefits null, partial responders to prior HCV therapy with peginterferon/ribavirin Healio Hepatology / 12 June 2013 Simeprevir boosts response to interferon-based hepatitis C therapy for prior relapsers Liz Highleyman / 03 June 2013 Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after three months, according to ... Vaniprevir boosts interferon/ribavirin response rate for prior non-responders with cirrhosis Liz Highleyman / 13 May 2013 The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at ... Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis Keith Alcorn / 30 April 2013 Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have only a moderate chance of being ... Hep C quad regimens quashed, but some components go forward Liz Highleyman / 29 April 2013 A pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive